A new therapy, RYDAPT (midostaurin), has been approved in Canada for persons with SM.  A review is being conducted to decide whether it should be included (paid for) in Canada's public drug plans. 

Have your voice heard by completing the survey!

Your feedback is urgently needed if you are a person living with Systemic Mastocytosis (SM) or a caregiver for a person with SM.  Canadian patients have the opportunity to provide input to the Canadian Agency for Drugs and Technologies in Health (CADTH) and specifically the panCanadian Oncology Drug Review (pCODR), the agency that will recommend (or not) whether RYDAPT (midostaurin) will be funded for SM patients.

Your responses will NOT be personally identified.  All responses will be summarized as part of the submission to CDR.  In our experience, the CDR committee listens very carefully to patient input.  Patient input is very important to assuring the committee makes the right decision.  This survey is being conducted by Mastocytosis Society Canada (MSC) with the support of the Canadian Organization for Rare Disorders (CORD).  Thank you in advance for your help.